-
Abemaciclib in heavily pre-treated HR+, HER2- Advanced Breast Cancer Patients線上課程內科用藥專業 1.0修課人數：109
分享台大團隊使用Abemaciclib於後線HR+, HER2- ABC病人的治療經驗
贊助廠商 台灣禮來股份有限公司more -
Treatment with SERD in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy線上課程內科用藥專業 1.0修課人數：105
Endocrine therapy is the fundamental treatment against this entity. Recent advances in novel compounds, such as cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), or phosphoinositide 3-kinase (PI3K) inhibitors have improved progression-free survival and overall survival in these patients. This presentation summarizes the evolution and ongoing studies in SERDs and new molecules against ER.
贊助廠商 賽諾菲股份有限公司more -
Utilizing subcutaneous formulation of anti HER2 therapies in breast cancer treatment線上課程內科用藥專業 1.0修課人數：80
HER2陽性的治療從療效出發，更提供病患在治療中的方便性，那就是皮下注射劑型的問世，Trastuzumab subcutaneous從各種面向的臨床試驗，提供患者療效及安全的臨床數據，並在過去3年中創造台灣臨床上HER2陽性病患治療的新模式。
贊助廠商 羅氏大藥廠股份有限公司more -
Transforming breast cancer treatment with PH FDC SC線上課程內科用藥專業 1.0修課人數：95
HER2陽性的治療從療效出發，更提供病患在治療中的方便性，那就是皮下注射劑型的問世，然而PH FDC更將臨床上需要分別注射的2種單株抗體透過專利的玻尿酸酶讓2種單株抗體合而為一，讓臨床上需要將近2小時的治療時間，縮短為5-8分鐘，增加醫療單位治療的流暢性增加、減少滯留醫院的等待期，PH FDC SC將創造台灣臨床上HER2陽性病患治療的新模式。
贊助廠商 羅氏大藥廠股份有限公司more -
Current Approaches and Future Perspectives of HER2 positive Early Breast Cancer Treatment-上集/下集線上課程內科用藥專業 2.0修課人數：105
以深入淺出的總覽這20年來Her2陽性乳癌的進展，從晚期轉移性乳癌的Trastuzumab進展至Pertuzumab+Trastuzumab的臨床應用，進一步新型態的ADC drug (trastuzumab emtansine)也對轉移性乳癌患者有更好的治療效果。從早期乳癌的治療演進，單標靶進而雙標靶都讓早期乳癌的患者擁有更好的長期存活率。
贊助廠商 羅氏大藥廠股份有限公司more -
When can we decline the use of anthracycline in HER2 positive early breast cancer?線上課程內科用藥專業 1.0修課人數：106
The management of HER2 positive breast cancer has rapidly evolved over the last 20 years. TRYPHAENA and TRAIN2 studies show the potential to omit anthracycline in the setting of dual HER2 blockade. The lecture will discuss the strategy of escalate and de-escalate treatment with less chemotherapy for early stage HER2 positive breast cancer.
贊助廠商more